Document:

Exhibit 10.56

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
 EXHIBIT 10.56

 CO-PROMOTION AGREEMENT 
 This Co-Promotion Agreement (this “Agreement”) is made and entered into effective as of January 28, 2011, by and between MAP Pharmaceuticals, Inc., a Delaware corporation
having an address at 2400 Bayshore Parkway, Suite 200, Mountain View, California 94043 (“MAP”), and ALLERGAN USA, Inc., a Delaware corporation having an address at 2525 Dupont Drive, Irvine, California 92612
(“ALLERGAN”). MAP and ALLERGAN are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 
 RECITALS 
 WHEREAS, ALLERGAN and MAP have entered into a
Collaboration Agreement dated January 28, 2011 (the “Collaboration Agreement”); 

WHEREAS, the Collaboration Agreement grants ALLERGAN certain co-exclusive rights to Commercialize Product to Physician
Targets for use in the Field in the Territory; and 
 WHEREAS, the Parties desire for MAP and ALLERGAN to
Commercialize Product to Physician Targets for use in the Field in the Co-Promotion Territory pursuant to the terms and conditions of this Agreement and the Collaboration Agreement. 

NOW, THEREFORE, in consideration of the foregoing promises and the mutual representations, warranties, covenants and
agreements contained herein and in the Collaboration Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 

ARTICLE 1 

DEFINITIONS 
 1.1    Definitions.  All capitalized terms not otherwise defined herein shall have the meaning given to them in the Collaboration Agreement. The following terms shall
have the meanings set forth next to them when used in this Agreement: 

(a)    “Co-Promotion Territory” means the United States of America. 

(b)    “DDMAC” means the Division of Drug Marketing, Advertising and Communication
of the FDA. 
 (c)    “Deficiency” means, for any Deficient Quarter, with
respect to the applicable Party, the percentage calculated using the following formula: ((A-B)/A), where A is the minimum number of PDEs assigned to such Party under the Collaboration Agreement or any then-current, mutually agreed upon
Commercialization Plan for such Calendar Quarter, and B is 

  
 [***]
Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
the number of PDEs actually delivered by the Sales Force of such Party during such Calendar Quarter. 
 (d)    “Deficient Quarter” means, with respect to a Party, the Calendar Quarter during which the Sales Force of such Party delivered fewer PDEs than the minimum number
of PDEs assigned to such Party for such Calendar Quarter under the Collaboration Agreement or any then-current, mutually agreed upon Commercialization Plan. 
 (e)    “FD&C Act” means the United States Food, Drug and Cosmetic Act, as amended from time to time (21 U.S.C. Section 301 et seq.), together with any rules
and regulations promulgated thereunder. 
 (f)    “Initial Three-Year
Period” means the three (3) year period immediately following First Commercial Sale. 

(g)    “Labeling” means (i) the FDA full prescribing information for Product in
the Field, including any required patient information, and (ii) all labels and other written, printed or graphic matter upon any container, wrapper or any package insert or outsert utilized with or for Product in the Field. 

(h)    “PDMA” means the Prescription Drug Marketing Act of 1987, as amended from
time to time, together with any rules and regulations promulgated thereunder. 

(i)    “Promotion Related Activities” means lunches, snacks, dinners, entertainment,
or medically related gifts for health care professionals with prescribing authority used to promote Product to such persons. For purposes of this Agreement, Promotion Related Activities expressly excludes conference or convention participation,
continuing medical education programs, grants, paid speaker programs, symposiums and entertainment. 

(j)    “Samples” means quantities of Product given to authorized medical
professionals for no or minimal consideration as part of the marketing, advertising and promotion of Product. 

(k)    “Training Materials” means the items the JCC develops or approves after the
Effective Date to train persons to promote Product in the Co-Promotion Territory. 
 ARTICLE 2 

CO-PROMOTION RIGHTS AND OBLIGATIONS 
 2.1    Co-Promotion Right.  As set forth herein and in the Collaboration Agreement, the Parties have the right and obligation to jointly Commercialize Product to
Physician Targets for use in the Field in the Co-Promotion Territory. 

2.2    Performance.  The Parties, through the JCC, will be responsible for the
day-to-day Commercialization activities for Product to Physician Targets for use in the Field in the Co-Promotion Territory. Subject to the terms of this Agreement and the Collaboration Agreement, the Parties shall have the right and responsibility
to field personnel and take actions related to 

  
 2 

 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Commercializing Product to Physician Targets for use in the Field in the Co-Promotion Territory during the Term, including the following: 

(a)    Each Party shall perform its respective obligations under this Agreement, the Collaboration
Agreement and the Commercialization Plan. 
 (b)    Following receipt of Regulatory Approval
of the Initial Indication in the Co-Promotion Territory, each Party shall use its Commercially Reasonable Efforts to Commercialize Product to Physician Targets in the Field in the Co-Promotion Territory and shall fulfill its obligations under this
Agreement and the Collaboration Agreement. The Parties shall deploy each of their respective Sales Forces in an effort to Commercialize Product to Physician Targets in the Field in the Co-Promotion Territory in accordance with the Commercialization
Plan in effect from time to time, the directions of the JCC, and the terms of this Agreement and the Collaboration Agreement. 
 (c)    Exhibit A to this Agreement sets forth the calculations of the following items which shall be incorporated into the initial Commercialization Plan: minimum Calendar Quarter
PDE requirements; PDE Rate; Calendar Quarter PDE expenses at PDE minimums; and Calendar Quarter PDE caps. Upon mutual written agreement of the Parties, the items and calculations may be adjusted for purposes of preparing any new Commercialization
Plans. In no event shall a Party be entitled to include as a Shared Expense or in the calculation of Net Sales, or otherwise be entitled to reimbursement for, any PDE Cost amount in excess of the Calendar Quarter PDE caps set forth on Exhibit A
(as may be amended from time to time). Upon the adjustment of the PDE ratios as provided in the definition of “PDE”, the Parties shall mutually agree upon appropriate and equitable adjustments in the calculations of the items on
Exhibit A to reflect such changes. 
 (d)    In implementing the obligations contained
in this Agreement, each Party shall [***] (which shall not be inconsistent with the Commercialization Plan, this Agreement and the Collaboration Agreement, and provided that neither Party will utilize any Promotional Materials not approved by the
JCC) in which it promotes and Details (including any expenditure of funds in connection therewith) Product in the Co-Promotion Territory. 
 (e)    Neither Party shall distribute or have distributed any information that bears the name or logo of the other Party without the prior approval of the other through the JSC or the
JCC, which approval shall not be unreasonably withheld, conditioned or delayed. 

2.3    Joint Commercialization Activities.  Subject to the requirements set forth in
the Collaboration Agreement and the then-current Commercialization Plan, each Party shall be responsible for performing Commercialization activities as described below: 

(a)     Commercialization Plan.  In addition to those items set forth in
Article 6 of the Collaboration Agreement and subject to the minimum obligations set forth herein and in the Collaboration Agreement, the Commercialization Plan shall specify with respect to Commercialization to Physician Targets for use in the
Field in the Co-Promotion Territory: 
 i.    Promotional Materials to be
used; 

  
 3 

 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 ii.    Subject to the minimum
requirements set forth herein and in the Collaboration Agreement, the number of PDEs that each Party and each respective Sales Force representative must perform in each Calendar Year; 

iii.    Detailing strategy and obligations of the Parties on a Calendar Year basis,
including (a) the “call plan” size (i.e., the number of Physician Targets to be called on by each Sales Force representative); (b) identification and prioritization of Physician Targets by deciles; (c) reach and frequency
expectations for the Physician Targets in each Calendar Period; and (d) the number and position of PDEs for Product to be performed in each Calendar Year; 

iv.    the reporting obligations of the Parties and their Sales Force representatives
with respect to the performance of their Commercialization activities under this Agreement, including the recording of Detailing activity by Sales Force representatives, the review by Sales Force representatives of the activities of their
counterparts on the other Party’s Sales Force, and the hardware, software and other information technology to be used therefor; 
 v.     sales forecasts for Product on a Calendar Quarter basis (or more frequently if so determined by the Parties); 

vi.    compensation packages for sales representatives including incentive
compensation; 
 vii.    Product pricing strategy and managed care and
reimbursement plans; 
 viii.   budget for such activities; and 

ix.    such other plans relating to Commercialization as the Parties deems necessary
or appropriate. 
 (b)    Sales Forces.  The Commercialization Plan will
set forth in reasonable detail all material matters related to Sales Force activities with respect to Product to Physician Targets in the Field in the Co-Promotion Territory. Subject to and in accordance with the provisions of this Agreement, the
Collaboration Agreement and the Commercialization Plan, each Party shall: 

i.    be solely responsible for recruiting, hiring, managing, maintaining,
disciplining, firing, compensating (including paying for all benefits, wages, special incentives, workers’ compensation, and employment taxes) and otherwise controlling its respective Sales Force and for paying for any and all costs associated
with its Sales Force’s efforts; 
 ii.    provide the day-to-day
management of its Sales Force, including, without limitation, furnishing administrative support, financial resources, equipment, and supplies, monitoring detail reporting and Sample accounting, and assuring the Sales

  
 4 

 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Force’s understanding and compliance with this Agreement, the Collaboration Agreement, the Commercialization Plan and Applicable Laws; 

iii.    utilize its Commercially Reasonable Efforts to deploy its Sales Force to
Commercialize to Physician Targets for use in the Field in the Co-Promotion Territory during the Term, after Regulatory Approval has been received for the Initial Indication for Product in the Field in the Co-Promotion Territory; and 

iv.    for the avoidance of doubt, at all times be obligated to meet such
Party’s minimum obligations as set forth in the Collaboration Agreement. 

(c)    Training.  The Parties shall establish procedures for jointly training sales
personnel and for preparation of Training Materials related to Commercialization of Product to Target Physicians in the Field in the Co-Promotion Territory. In addition, the Parties shall be responsible for preparing all sales Training Materials
with regard to Product to Physician Targets for use in the Field in the Co-Promotion Territory, such training to include a reasonable proficiency examination. Both Parties agree to utilize only sales Training Materials that have been approved by
each Party’s respective legal and regulatory departments. Training shall include a home study period and an initial classroom-setting training program, which shall include medical and technical information about use of Product in the Field in
the Co-Promotion Territory. The Parties shall direct which personnel shall receive training on the use of Product in the Field and which Party shall perform the training. Only personnel who have passed the proficiency examination with a minimum
[***] proficiency are qualified to Commercialize Product to Physician Targets for use in the Field in the Co-Promotion Territory. The Parties shall share training costs as set forth in the Collaboration Agreement. The Parties acknowledge that their
respective Sales Forces must be trained, qualified and ready to launch, Commercialize and Detail Product to Physician Targets for use in the Field in the Co-Promotion Territory on the date of launch as specified in the then-current Commercialization
Plan; provided that such date shall be no later than the date specified for such Party in the Collaboration Plan. 
 (d)    Sales Force Meetings.  The Parties will work together to coordinate the timing and location of Sales Force meetings regarding Product. The Parties shall have at
least one (1) joint national sales meeting per Calendar Year. If such national sales meeting involves products other than Product, ALLERGAN shall not have the right to participate in those sections that specifically relate to the other MAP
products, and MAP shall not have the right to participate in those sections that specifically relate to the other ALLERGAN products. The Parties shall share Sales Force meeting costs as set forth in the Collaboration Agreement. 

(e)    Sales Territories.  The sales territories, sales districts, and sales regions
for the [***] sales territories, sales districts and sales regions for [***]. If [***] its territories, sales districts or sales regions [***] shall in good faith consider the [***], but shall not be obligated to [***] for each state, territory,
possession and protectorate within the [***]. 
 (f)    Samples.  The
Parties shall determine the appropriate level of and process for Product sampling. MAP shall supply all Samples, the costs and expenses of which are included in Shared Expenses, subject to the provisions of the Collaboration Agreement. Each

  
 5 

 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Party will transport, store, handle and distribute all Samples, as may be determined by the Parties, in compliance with Applicable Laws and with the procedures established by the JCC. 

(g)    Compensation. 

i.    Each Party shall use its Commercially Reasonable Efforts to ensure that
variable pay components of its compensation structure, including but not limited to incentives (“Incentive Compensation”), for its Sales Force with responsibility for Commercializing Product are consistent with practices used for
other similar products. To facilitate the determination of Product incentives, the Parties will work together to coordinate annual sales plans. 
 ii.    In furtherance of and without limiting the foregoing, MAP shall allocate [***] of Sales Force Incentive Compensation to Product for the shorter of [***], and [***]. 

iii.    Notwithstanding anything contained in this Agreement or in the Collaboration
Agreement, ALLERGAN will allocate [***] of ALLERGAN Sales Force Incentive Compensation to Product [***]. 

(h)    Promotion of Other Products.  Subject to the provisions of this Agreement,
while this Agreement is in effect, each Party has the right to have its Sales Force Detail products other than Product in any detail positions not reserved by the Parties for Product. [***]. 

(i)    Product Complaints.  The Parties will establish appropriate procedures for
handling and reporting of Product complaints. 
 (j)    Medical
Inquiries.  The Parties will establish appropriate procedures for dealing with medical inquiries related to Product. 
 (k)    Managed Care.  The Parties shall coordinate activities with respect to Product across managed care market segments in the Field in the Co-Promotion Territory
including: (i) contract strategy, (ii) contract creation; (iii) government reporting, rebate processing, calculations and pricing schedules; (iv) contract compliance, monitoring and audits; (v) contract administration and
claims processing; and (vi) all other matters related to managed care. [***] to Detail or otherwise Commercialize Product to any Physician Targets or to any contracting agents, medical directors, formulary decision makers, benefit managers, or
administrators (even if such persons are health care professionals legally authorized to prescribe Product) of a managed care organization (e.g., health maintenance organization, prescription benefits manager, insurance company, or similar entity),
government-funded insurance or medical program, or employer. All Product Commercialization and contracting activities with managed care entities will be conducted by the designated Party. 

(l)    Conflicts Between Agreements.  For the avoidance of doubt and notwithstanding
any provision contained herein, in the Collaboration Agreement, or in the then-applicable Commercialization Plan, the minimum obligations set forth in any Commercialization 

  
 6 

 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Plan shall equal or exceed the minimum obligations of the Parties, respectively, set forth in this Agreement and the Collaboration Agreement, unless expressly agreed upon in a written document
signed by both Parties. In the event of any discrepancy between this Agreement and the Collaboration Agreement, on the one hand, and any Commercialization Plan, on the other, the terms and conditions of this Agreement and the Collaboration Agreement
(taking into account the provisions of Section 7.1 hereof) shall control. 

2.4    Consequences of Failure to Perform Required PDEs. 

(a)    Detail Deficiencies.  For any Deficient Quarter or Deficient Quarters in
which a Party’s Sales Force delivers fewer than [***] of the minimum PDEs assigned to it under the Collaboration Agreement or in the then-current, mutually agreed upon Commercialization Plan for such Calendar Quarter or Calendar Quarters:

 i.    If a Party fails to perform at least [***]of the aggregate minimum
required PDEs for Product for the then-current Calendar Quarter, but performs at least [***] of such required PDEs, then the Party shall be entitled to carry such PDE Deficiencies forward to the following Calendar Quarter. Deficiencies that are
carried forward to the next Calendar Quarter shall be included in the calculation of the PDEs assigned in the successive Calendar Quarters, until satisfied in full. 

ii.    If a Party fails to perform at least [***] of the aggregate minimum required
PDEs for Product for the then-current Calendar Quarter, then the other Party shall be entitled to a credit equal to the difference between [***] of the minimum required PDEs and the actual PDEs performed, such number of PDEs then multiplied by
[***], which shall be credited to the other Party’s share of Distributable Profit or Distributable Loss. 

(b)    If either Party is more than [***] Deficient in [***], then such Party will be deemed to have
not used Commercially Reasonable Efforts in Commercializing Product and the other Party shall have the right to terminate this Agreement and the Collaboration Agreement upon written notice; provided, that any such termination shall not affect the
right of the Party terminating the Agreement from pursuing any and all other remedies that may be available to it. 
 (c)    Each Party shall be entitled to audit the records of the other Party (as well as the records of the other Party’s subcontractors) to verify such other Party’s delivery
of PDEs under this Agreement pursuant to the audit provisions of the Collaboration Agreement. 

2.5    Promotional Materials. 

(a)    The Parties shall establish a tracking system for Promotional Materials to ensure that all
such Promotional Materials are accurately tracked and submitted to the FDA. MAP will file all Promotional Materials with the FDA if, and as required, by FDA regulations. According to the agreed Commercialization Plan the JCC shall oversee the
development and production of all written, printed, electronic and graphic promotional materials including all product labels and inserts to be used by the Parties. Both Parties agree to utilize only

  
 7 

 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Promotional Materials that have been approved by each Party’s respective legal and regulatory departments. 

(b)    The Parties shall not create, develop or distribute any sales, promotional content or other
similar materials (including Labeling) relating to Product for Commercialization to Target Physicians in the Field in the Co-Promotion Territory except as set forth in this Section. All oral communications that the Parties or its Sales Force has
with Third Parties relating to Product shall conform to the pre-approved talking points (which shall be the same for the Sales Force of both Parties) as recommended by the JCC and shall be subject to review by the JSC. 

2.6    Cessation of Use of Materials.  If the Party responsible for Training
Material, Promotional Material or Samples informs the JCC in writing that a Training Material, Promotional Material, or Sample may no longer be used or distributed, each Party agrees that it will not allow its Sales Force to use or distribute such
Training Material, Promotional Material, or Sample after the no-use date identified by the responsible Party in its notice. 

ARTICLE 3 

SALES AND EXPENSES 
 3.1    Sales and Distribution.  Through the JCC, the Parties will establish the terms and conditions with respect to the Commercialization of Product to Physician
Targets for use in the Field in the Co-Promotion Territory, including, without limitation, [***]. 

3.2    Sales Budget.  As set forth in the Collaboration Agreement, Sales Force
members shall be reimbursed at an FTE Rate equal to [***] per FTE, which amount may be subject to change from time to time during the Term upon mutual agreement of the Parties. 
 ARTICLE 4 
 OPERATING PROCEDURES 

4.1    Exchange of Information. 

(a)    Exchange of Information Generally.  Each Party shall provide the other Party
with such information as the other Party may reasonably request during the Term in order to support the requesting Party’s Sales Force’s Commercialization and Detailing of Product to Physician Targets for use in the Field in the
Co-Promotion Territory. During the Term and subject to the provisions of this Agreement, each Party will provide the other with all information that the disclosing Party reasonably deems significant and relevant to the Commercialization and
Detailing of Product to Physician Targets for use in the Field in the Co-Promotion Territory within a reasonable time after such information becomes known to the Party; provided, however, that such information is not received from an independent
Third Party under a confidentiality obligation. The JCC shall establish reasonable procedures for monitoring of Sales Force activities to ensure that each Party is complying with its obligations under this Agreement. 

  
 8 

 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (b)    Electronic Reporting.  The
Parties shall utilize an electronic sales force automation system for data collection and data management consistent with industry standard practices to produce reports and analyses of their respective Sales Force’s activities and Product
performance with Physician Targets in the Field in the Co-Promotion Territory. The Parties shall provide an electronic call reporting system to each member of their respective Sales Force. The deployed system shall be in compliance with Applicable
Laws. Each Sales Force member shall produce detailed electronic notes following each Detail. Each Sales Force member shall be responsible for Detail planning and Detail routing, using sales data to plan, monitor and measure territory performance, as
well as reporting useful marketing information obtained for Product in the Co-Promotion Territory, [***]. Within thirty (30) days after the end of each calendar month, the Parties will share reports summarizing Sales Force activity collected
from such electronic call reporting system(s) in the prior calendar month. Specific reportable information shall at a minimum include: (i) total number of PDEs reported for each Sales Force member, by month, by Calendar Quarter and
year-to-date; (ii) aggregate PDEs by month, by Calendar Quarter and year-to-date to each unique member of Physician Targets; and (iii) roll-up of each Party’s monthly, Calendar Quarter and year-to-date aggregate PDEs versus the
monthly, by Calendar Quarter and year-to-date goal as specified in the then-current Commercialization Plan. Such information shall be reported in a Microsoft Excel electronic file format or such other format as reasonably agreed by the Parties.

 (c)    Other Reporting.  The Parties shall report to each other all
information necessary to permit each Party to make timely reports as required by any governmental regulatory agency regarding Product. Each Party shall promptly communicate to the other Party all comments, statements, requests and inquiries of the
medical profession or any other Third Parties relating to Product in the Field in the Co-Promotion Territory that are out of the ordinary, or not covered by the Labeling, of which such Party becomes aware. All responses to such inquiries of the
medical profession or such other Third Parties within the Co-Promotion Territory shall be handled as designated by the JCC. The Parties shall refer all medical inquiries concerning Product in the Field and all quality complaints within the
Co-Promotion Territory to a designated address and/or telephone number agreed upon by the Parties. 

4.2    Compliance. 

(a)    The Parties shall conform their practices and procedures relating to Commercializing and
Detailing of Product in the Field in the Co-Promotion Territory to policies and procedures, as determined by the JCC from time to time (the “Policies”), but in no event less than the requirements of all applicable Laws and
guidelines, including the FD&C Act, the PDMA, the requirements of DDMAC, the Federal Health Care Programs Anti-Kickback Law, 42 U.S.C. 1320a-7b(b), the Pharmaceutical Research and Manufacturers of America (“PhRMA”) Code of
Pharmaceutical Marketing Practices (the “PhRMA Code”) and the American Medical Association (“AMA”) Guidelines on Gifts to Physicians from Industry (the “AMA Guidelines”), as the same may be amended
from time to time. Each Party shall promptly notify the other Party of and provide the other Party with a copy of any correspondence or other reports with respect to Commercializing, Detailing and/or promotion of Product in the Field in the
Co-Promotion Territory submitted to or received from the U.S. Department of Health and 

  
 9 

 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Human Services or its components (including the FDA and the Office of the Inspector General), PhRMA or the AMA relating to such Laws and guidelines. 

(b)    The Parties shall in all material respects conform their practices and procedures relating to
educating the medical community in the Co-Promotion Territory with respect to Product in the Field in the Co-Promotion Territory to the Policies, the Accreditation Council for Continuing Medical Education (“ACCME”) Standards for
Commercial Support of Continuing Medical Education (the “ACCME Standards”) and any applicable FDA regulations or guidelines, as the same may be amended from time to time. Each Party shall promptly notify the other Party of and
provide the other Party with a copy of any correspondence or other reports submitted to or received from the ACCME with respect to Product in the Field in the Co-Promotion Territory relating to the ACCME Standards or such FDA regulations or
guidelines. 
 (c)    The Parties shall provide each member of its Sales Force (prior to
performance of services hereunder), with a copy of the then-current code of ethics of the respective Party. The Parties shall ensure that each member of its Sales Force acknowledges in writing receipt of, and will comply with, the then-current code
of ethics in performing services under this Agreement and the Collaboration Agreement. 

(d)    In connection with Commercialization and Detailing of Product hereunder, neither Party nor any
member(s) of their respective Sales Forces shall knowingly make any false or misleading statement, or make any representation or warranty, oral or written, to Third Parties, concerning Product that is inconsistent with, or contrary to, the Labeling
or Promotional Materials or that is disparaging to Product, the other Party, or any of other Party’s Affiliates, officers, directors or employees. 
 4.3    Independent Contractors.  For all purposes, and notwithstanding any other provisions of this Agreement to the contrary, the legal relationship under this
Agreement of the Parties shall be that of independent contractors. It is further understood and agreed that the Parties are engaged in the operation of their own respective businesses, and neither Party is to be considered the agent of the other
Party for any purpose whatsoever. Neither Party will have any authority to enter into any contracts or assume any obligations for the other Party nor make any warranties or representations on behalf of that other Party. 

ARTICLE 5 

REPRESENTATIONS, WARRANTIES AND COVENANTS 
 5.1    The Parties’ Representations and Warranties.  Each Party hereby represents, warrants and covenants to the other Party that: 

(a)    it is not debarred under the Generic Drug Enforcement Act of 1992 (the “GDE
Act”) and is in compliance with the provisions of the GDE Act; 
 (b)    while this
Agreement is in effect, it will comply with the GDE Act, will not become debarred under the GDE Act, and will not use in connection with this Agreement the services of any person or entity debarred under the GDE Act; 

  
 10 

 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (c)    upon request by the other Party, a Party will
certify its compliance with the GDE Act and this Section in writing to such other Party; 

(d)    no employee or representative of a Party shall have any authority to bind or obligate the
other Party to this Agreement for any sum or in any manner whatsoever, or to create or impose any contractual or other liability on the other Party without the other Party’s authorized written approval. 

5.2    MAP Representations, Warranties, and Covenants.  MAP represents, warrants and
covenants that: 
 (a)    MAP has or shall have at the time required the requisite
personnel, facilities, equipment, expertise, experience and skill to perform its obligations hereunder and to render the services contemplated hereby; 
 (b)    MAP and its Sales Force shall perform the services in a professional, timely, competent and efficient manner, and it and its Sales Force shall abide by all Laws that apply to
its and their performance; 
 (c)    any negligent or wrongful act or omission on the part
of MAP’s Sales Force (both individually and as a group) shall be deemed to be negligent or wrongful acts or omissions of MAP. MAP shall notify ALLERGAN in writing as promptly as practicable of any alleged negligent or wrongful acts or omissions
on the part of MAP’s Sales Force, and of any allegations of negligent or wrongful acts or omissions made against ALLERGAN’s Sales Force; and 
 (d)    at the time MAP delivers Samples to ALLERGAN, MAP represents and warrants to ALLERGAN that such Samples: 

i.     comply in all material respects with the Product Specifications;

 ii.    comply in all material respects with the FD&C Act; 

iii.   are not products that have been adulterated or misbranded within the meaning set
forth in FD&C Act and any state or local law or regulation substantially similar to FD&C Act; 
 iv.    are products that may be introduced into interstate commerce; and 
 v.     have been manufactured, packaged, stored, and shipped in conformity with all applicable cGMP. 

5.3    ALLERGAN Warranties and Covenants.  ALLERGAN warrants and covenants that:

  
 11 

 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 (a)    ALLERGAN has the requisite personnel, facilities,
equipment, expertise, experience and skill to perform its obligations hereunder and to render the services contemplated hereby; 
 (b)    ALLERGAN and its Sales Force shall perform such services in a professional, timely, competent and efficient manner, and it and its Sales Force shall abide by all Applicable Laws
that apply to its and their performance; and 
 (c)    any negligent or wrongful act or
omission on the part of ALLERGAN’s Sales Force (both individually and as a group) shall be deemed to be negligent or wrongful acts or omissions of ALLERGAN. ALLERGAN shall notify MAP in writing as promptly as practicable of any alleged
negligent or wrongful acts or omissions on the part of ALLERGAN’s Sales Force, and of any allegations of negligent or wrongful acts or omissions made against MAP’s Sales Force. 

5.4    Notice of Breach.  If, at any time, a Party is aware that it has materially
breached a representation, warranty or covenant under this Agreement, the breaching Party will promptly notify the other Party of such material breach. 
 5.5    Performance by Affiliates.  The Parties recognize that a Party may perform some or all of its obligations under this Agreement through its Affiliates.

 5.6    DISCLAIMER OF ALL OTHER WARRANTIES.  THE WARRANTIES SET FORTH IN
THIS AGREEMENT AND THE COLLABORATION AGREEMENT ARE THE PARTIES’ ONLY WARRANTIES WITH RESPECT HERETO AND ARE MADE EXPRESSLY IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, WHICH ARE HEREBY DISCLAIMED, INCLUDING ANY IMPLIED WARRANTIES OF
FITNESS FOR A PARTICULAR PURPOSE, MERCHANTABILITY, OR OTHERWISE. 
 5.7    LIMITATION OF
LIABILITY.  WITHOUT LIMITING THE PARTIES’ INDEMNIFICATION OBLIGATIONS UNDER THE COLLABORATION AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES
(INCLUDING WITHOUT LIMITATION DAMAGES RESULTING FROM LOSS OF USE, LOSS OF PROFITS, INTERRUPTION OR LOSS OF BUSINESS, OR OTHER ECONOMIC LOSS) ARISING OUT OF THIS AGREEMENT OR WITH RESPECT TO A PARTY’S PERFORMANCE OR NON-PERFORMANCE HEREUNDER.

 ARTICLE 6 
 TERM AND TERMINATION 

6.1    Term.  The term of this Agreement shall commence on the Effective Date and
continue until the earlier of (a) termination of the Collaboration Agreement or (b) the date on which this Agreement is terminated pursuant to the provisions herein (the “Term”). 

6.2    Effect of Termination or Expiration.  Termination or expiration of this
Agreement in whole or in part shall not relieve the Parties of any amounts owing between them 

  
 12 

 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
at the date termination or expiration. Upon termination or expiration of this Agreement, ALLERGAN shall, at its sole expense and within thirty (30) days of such termination or expiration,
return to MAP all Promotional Materials and any Samples of Product then in the possession of ALLERGAN and any of its Sales Force; provided, however, that ALLERGAN shall be entitled to retain one (1) copy of such Promotional Materials,
(a) to the extent reasonably required to allow ALLERGAN to carry out any remaining obligations under this Agreement or the Collaboration Agreement or to exercise any of its rights that expressly survive termination or expiration of this
Agreement or the Collaboration Agreement, and (b) for legal archival purposes and/or as may be required by Applicable Law. The following provisions shall survive any termination or expiration of this Agreement: Articles 1 and 7 and
Sections 2.3(l), 5.6, 5.7 and 6.2. 
 ARTICLE 7 

GENERAL PROVISIONS 
 7.1    Incorporation of Terms from the Collaboration Agreement.  This Agreement forms an integral part of the Collaboration Agreement, and is incorporated into the
Collaboration Agreement. As a part of the Collaboration Agreement, this Agreement is subject to all terms and conditions of the Collaboration Agreement. Without limiting the generality of the foregoing, Article 6 and Article 18 of the
Collaboration Agreement each apply to this Agreement as if stated herein. In the event of any contradictions or inconsistencies between the terms of this Agreement and those of the Collaboration Agreement, the terms of the Collaboration Agreement
shall govern. 
 7.2    Addition of Canada to Territory.  The Parties
acknowledge and agree that if Canada becomes part of the Territory in accordance with the terms of the Collaboration Agreement, the Parties or their respective Affiliates will enter into a separate co-promotion agreement with respect to Canada, or
amend this Agreement to include terms that are specific to Canada and the Parties’ (or their respective Affiliates’) obligations with respect to promotion of Product in Canada, in accordance with the Collaboration Agreement. 

  
 13 

 [***] Certain information in this document has been omitted and filed separately
with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 In Witness Whereof, the Parties have as of the date first set forth
above duly executed this Agreement. 
  

									
	ALLERGAN USA, INC.	 		 	MAP PHARMACEUTICALS, INC.
					
	By:	 	/s/ David E.I. Pyott	 		 	By:	 	/s/ Timothy S. Nelson
					
	Name:	 	David E.I. Pyott	 		 	Name:	 	Timothy S. Nelson
					
	Title:	 	Chief Executive Officer	 		 	Title:	 	President and CEO

  
 [***]
Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 EXHIBIT A 
 Calculations for Certain Items in Initial Commercialization Plan 
  

							
	  	  	Allergan	  	MAP	  	  
	 			 
	 Minimum Calendar Quarter PDE Requirements
	  	[***]	  	[***]	  	 
	 PDE Rates
	  	[***]	  	[***]	  	 
	 Calendar Quarter PDE Expense at PDE Minimum
	  	[***]	  	[***]	  	 
	 Calendar Quarter PDE Expense
Cap
	  	[***]	  	[***]	  	 

  
 [***]
Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.Letter Agreement dated February 28,2011

 Exhibit 10.1 

 

			
	To:	  	Bank Handlowy w Warszawie S.A.
		  	Departament Operacji Kredytowych
		  	ul. Goleszowska 6
		  	01-260 Warsaw
		
		  	Bank Zachodni WBK S.A.
		  	ul. Grzybowska 5a
		  	00-132 Warsaw

 28 February 2011

  

	Re:	PLN 330,000,000.00 Term and Overdraft Facilities Agreement dated 17 December 2010 between, amongst others, Bank Zachodni WBK S.A. as original lender (“Bank
Zachodni WBK”), Bank Handlowy w Warszawie S.A. as agent, original lender and security agent (“Bank Handlowy”), Central European Distribution Corporation, CEDC International sp. z o.o., Przedsiębiorstwo “Polmos”
Białystok S.A. and PWW sp. z o.o. (the “Facilities Agreement”) 

 Dear Sirs, 

We write to you in respect of the Facilities Agreement. Capitalized terms used in this letter shall have the same meaning as provided for in the
Facilities Agreement, unless explicitly provided otherwise herein. References to “Clauses” are references to the respective Clauses of the Facilities Agreement. 
 As you are aware, Central European Distribution Corporation (“CEDC”) intends to revise its 2011 budget based in part on its full year 2010 preliminary results. The Finance Parties have
been provided with and have reviewed information prepared by CEDC in respect of its 2010 results and 2011 budget. As a result of several factors in the fourth quarter of 2010, most notably problems with the supply of excise stamps in Russia, costs
related to the launch of Zubrowka Biala in Poland, and increases in spirit pricing, CEDC’s quarterly and full year results did not match earlier expectations. Those issues have been discussed with the Finance Parties during the presentation by
CEDC. 
 As a result, the Borrowers have requested, with the consent of all other Obligors, that the Agent procure agreement from the Finance
Parties for a waiver of certain Defaults or the Events of Default that occurred or may occur under the Facilities Agreement. 
 On the basis set
forth in this letter agreement, the Finance Parties agree to waive the Waived Obligations (as defined below), and the Obligors further agree with the Finance Parties (the Obligors and the Finance Parties are referred to herein collectively as the
“Parties”) to undertake certain other acts and obligations as set forth herein. 
 Waiver 

Subject to the terms and conditions in paragraphs 1 to 8 below, the Finance Parties agree to waive the Waived Obligations (as defined below). 

  
 - 1 -

	1.	The waiver shall only be granted by the Finance Parties with respect to: (i) the Consolidated Coverage Ratio and Net Leverage Ratio financial covenants in Clause
23.2 for the Calculation Period ending on 31 December 2010, and (ii) any Default or Event of Default under Clause 25.2.1 and limited solely to breach of requirement of Clause 23 (Financial covenants) of the Facilities Agreement and
arising out of or related to the financial results of the Group for 2010 (in each case to be reflected in the Compliance Certificate to be delivered to the Agent as provided in Clause 22.4 on the date provided in Clause 22.3.1) (collectively the
“Waived Obligations”). 

  

	2.	The financial covenants referred to in Clause 23.2 of the Facilities Agreement applicable to the Calculation Period ending on 31 March 2011 shall be amended and
shall be as follows: 

  

	 	(a)	the Net Leverage Ratio shall not exceed 8.35:1, 

  

	 	(b)	the Consolidated Coverage Ratio shall not be less than 1.28:1. 

  

	3.	The Obligors hereby confirm that as at the date hereof all Repeating Representations set out in the Facilities Agreement are true and correct, and that the Obligors
comply with all provisions of the Facilities Agreement (other than in respect of the Waived Obligations). 

  

	4.	The Investor and the Obligors hereby confirm that the Investor and none of the Obligors are in “Default” under the Indenture (as such term is defined in the
Indenture). 

  

	5.	As of the date of this letter agreement, the Facility B Commitment and the Facility C Commitment shall be pro rata reduced to the total level of PLN 120,000,000.
All commitment fees payable by the Borrowers in relation to Facility B and Facility C also shall be reduced pro rata. Subject to the satisfactory, in the Finance Parties’ sole opinion, conclusions of the due diligence process referred to
in paragraph 9, the Facility B Commitment and the Facility C Commitment may be increased up to the initial level of PLN 200,000,000 without any additional arrangement fees. At such time, all commitment fees payable by the Borrowers in relations to
Facility B and Facility C also shall be increased pro rata. 

  

	6.	Not later than 5 Business Days from the date hereof, the Borrowers shall pay to the Agent on the account of Finance Parties a non-refundable waiver fee in the amount of
PLN 3,300,000 (one-off fee). The amount of each Original Lender’s share of the waiver fee will be its pro rata share in the Commitment. The Finance Parties shall not demand any additional waiver fee in 2011 in relation to any other
waiver that may be requested and given in relation to any breach of the financial covenants set out in the current wording of the Facilities Agreement that may potentially occur in line with the agreed financial plan for 2011.

  

	7.	With the effect from 1 March 2011, the Margin shall be increased and shall amount to 4.25 per cent. per annum in relation to Facility A, 3.25 per cent.
per annum in relation to Facility B and Facility C and 2,50 per cent. per annum in relation to the Letters of Credit issued after 1 March 2011. Subject to the satisfactory, in the Finance Parties’ sole opinion, conclusions of the due
diligence process referred to in paragraph 9, the Margin may be reduced. 

  
 - 2 -

	8.	The Finance Parties shall receive, in form and substance satisfactory to them, on or before 2 March 2011, a legal opinion of Dewey & LeBoeuf LLP, as legal
advisors to the Obligors as to the matters of the laws of the state of New York (USA), confirming that this letter agreement is not a violation of any provisions of the Indenture. 

Other Undertakings 
 The Obligors
hereby further agree to the following undertakings: 
  

	9.	The Finance Parties shall be allowed to immediately launch and carry, out at the cost and expense of the Obligors, due diligence on the situation of the Group and the
Obligors. Within 30 days from the date hereof, the Finance Parties will appoint, at the cost and expense of the Obligors, an independent, professional and reputable consulting company (“External Advisor”) in order to assist with the
due diligence. The Obligors and the Investor shall: (i) cooperate in good faith amongst themselves, with the Finance Parties and the External Advisor and do all acts and things reasonably necessary or desirable in the opinion of the Finance
Parties in order to carry out and complete the due diligence process and (ii) promptly deliver any and all documents and information reasonably (in the Finance Parties’ opinion) requested by the Finance Parties or the External Advisor in
connection with such due diligence. The due diligence process shall be completed not later than on 31 May 2011. Following the delivery of the due diligence report, the Parties agree to cooperate in good faith to reach an agreement on the
revised terms and conditions of the Facilities Agreement by 30 June 2011. Should the agreement on the revised terms and conditions of the Facilities Agreement be not signed by 30 June 2011, the Lenders may, by written notice to the
Obligors’ Agent given not earlier than 29 July 2011, cancel the Facilities (pursuant to Clause 25.20.1(d)) and terminate the Facilities Agreement (pursuant to Clause 25.20.1(a)) and declare the Advance and the Overdraft Outstanding
Amounts, together with accrued interest, and all other amounts accrued under the Finance Documents, due and payable (pursuant to Clause 25.21(a)) within 3 days from such notice. 

 

	10.	The Finance Parties shall be allowed to monitor, on a monthly basis, the financial standing of the individual Obligors and the Investor against the Investor’s
updated financial plan for 2011 (the copies of which, duly signed by the Investor, were delivered to the Finance Parties prior to the date hereof), in particular, without limitation, by reviewing the cash flow, sales and liquidity reports as well as
lines utilization of the individual Obligors and the Investor, and the Obligors and the Investor shall cooperate in good faith and do all acts and things reasonably necessary or desirable in the opinion of the Finance Parties in order to carry out
the monitoring and shall promptly deliver any and all documents reasonably (in the Finance Parties’ opinion) requested by the Finance Parties and within the scope and in the form requested by the Finance Parties and relating to, amongst others,
the financial standing of the individual Obligors and the Investor and the execution of submitted forecasts. 

  

	11.	The Obligors shall promptly pay all costs and expenses (including all documented and pre-agreed legal fees) incurred by the Finance Parties in connection with the
preparation and negotiation and performance of this letter agreement. 

  
 - 3 -

 Other Matters 
  

	12.	Nothing in this letter agreement shall affect the rights of the Finance Parties in respect of the occurrence of any Default other than the Waived Obligations, whether
arising prior to, on or after the date of this letter agreement. 

  

	13.	The fact that the Finance Parties have allowed or may allow further drawings under the Facilities shall not be read as their waving of any rights they may have under
the Finance Documents other than in respect of the Waived Obligations. 

  

	14.	The provisions of Clause 32 (Notices), Clause 34 (Partial Invalidity), Clause 35 (Remedies and waivers) and Clause 39 (Enforcement) of the
Facilities Agreement shall be incorporated into this letter agreement as if set out in full in this letter agreement, and as if references in those clauses to “this Agreement” or “the Finance Documents” are references to this
letter agreement. 

  

	15.	This letter agreement may be executed in any number of counterparts, and this has the same effect as if the signatures on the counterparts were on a single copy
thereof. 

  

	16.	This letter agreement is a “Finance Document” for the purpose of the Facilities Agreement. 

 

	17.	This letter agreement is governed by Polish law. 

  

	18.	If the terms of this letter agreement are satisfactory, please indicate your acceptance by signing a copy hereof in the place indicated below and returning it to our
office. 

 [Signature Pages Follow] 

  
 - 4 -

 Acting in the name of CEDC International sp. z o.o. as Borrower: 

 

					
	Przemyslaw Witas	  	General Counsel of CEDC Group and Proxy	  	February 28, 2011    /s/ Przemyslaw Witas
	Name	  	Position	  	Date and signature

  
 - 5 -

 Acting in the name of PWW sp. z o.o. as Borrower: 

 

					
	Przemyslaw Witas	  	General Counsel of CEDC Group and Proxy	  	February 28, 2011    /s/ Przemyslaw Witas
	Name	  	Position	  	Date and signature

  
 - 6 -

 Acting in the name of Przedsiębiorstwo “Polmos” Białystok sp. z o.o. as Borrower:

  

					
	Przemyslaw Witas	  	General Counsel of CEDC Group and Proxy	  	February 28, 2011    /s/ Przemyslaw Witas
	Name	  	Position	  	Date and signature

  
 - 7 -

 Acting in the name of CEDC as Original Guarantor: 

 

					
	Przemyslaw Witas	  	General Counsel of CEDC Group and Proxy	  	February 28, 2011    /s/ Przemyslaw Witas
	Name	  	Position	  	Date and signature

  
 - 8 -

 Acting in the name of Limited Liability Company “The Trading House “Russian Alcohol” as
Guarantor: 
  

					
	Przemyslaw Witas	  	General Counsel of CEDC Group and Proxy	  	February 28, 2011    /s/ Przemyslaw Witas
	Name	  	Position	  	Date and signature

  
 - 9 -

 Acting in the name of Joint Stock Company “Distillery Topaz” as Guarantor: 

 

					
	Przemyslaw Witas	  	General Counsel of CEDC Group and Proxy	  	February 28, 2011    /s/ Przemyslaw Witas
	Name	  	Position	  	Date and signature

  
 - 10 -

 Acting in the name of ZAO “Sibirsky LVZ” as Guarantor: 

 

					
	Przemyslaw Witas	  	General Counsel of CEDC Group and Proxy	  	February 28, 2011    /s/ Przemyslaw Witas
	Name	  	Position	  	Date and signature

  
 - 11 -

 Acting in the name of OOO “First Tula Distillery” as Guarantor: 

 

					
	Przemyslaw Witas	  	General Counsel of CEDC Group and Proxy	  	February 28, 2011    /s/ Przemyslaw Witas
	Name	  	Position	  	Date and signature

  
 - 12 -

 Acting in the name of “The Trading House “Russian Alcohol-Center” LLC as Guarantor:

  

					
	Przemyslaw Witas	  	General Counsel of CEDC Group and Proxy	  	February 28, 2011    /s/ Przemyslaw Witas
	Name	  	Position	  	Date and signature

  
 - 13 -

 Acting in the name of “The Trading House “Russian Alcohol North-West” LLC as Guarantor:

  

					
	Przemyslaw Witas	  	General Counsel of CEDC Group and Proxy	  	February 28, 2011    /s/ Przemyslaw Witas
	Name	  	Position	  	Date and signature

  
 - 14 -

 Acting in the name of Closed Joint Stock Company Mid-Russian Distilleries as Guarantor: 

 

					
	Przemyslaw Witas	  	General Counsel of CEDC Group and Proxy	  	February 28, 2011    /s/ Przemyslaw Witas
	Name	  	Position	  	Date and signature

  
 - 15 -

 Acting in the name of Limited Liability Company “Parliament Production” as Guarantor: 

 

					
	Przemyslaw Witas	  	General Counsel of CEDC Group and Proxy	  	February 28, 2011    /s/ Przemyslaw Witas
	Name	  	Position	  	Date and signature

  
 - 16 -

 Acting in the name of Limited Liability Company “Parliament Distribution” as Guarantor:

  

					
	Przemyslaw Witas	  	General Counsel of CEDC Group and Proxy	  	February 28, 2011    /s/ Przemyslaw Witas
	Name	  	Position	  	Date and signature

  
 - 17 -

 Acting in the name of “Bravo Premium” LLC as Guarantor: 

 

					
	Przemyslaw Witas	  	General Counsel of CEDC Group and Proxy	  	February 28, 2011    /s/ Przemyslaw Witas
	Name	  	Position	  	Date and signature

  
 - 18 -

 We hereby agree to this letter agreement. 
 Acting in the name of Bank Handlowy w Warszawie S.A. as the Original Lender and the Agent: 
  

					
	Sebastian Perczak	  	  	  	February 28, 2011    /s/ Sebastian Perczak
	Name	  	Position	  	Date and signature

  

					
	Piotr Kosno	  	  	  	February 28, 2011    /s/ Piotr Kosno
	Name	  	Position	  	Date and signature

 Acting in the name of Bank Zachodni
WBK S.A. as the Original Lender: 
  

					
	Name Illegible	  	Director and Proxy	  	February 28, 2011    /s/ Signature Illegible
	Name	  	Position	  	Date and signature

  

					
	Artur Chodacki	  	Director and Proxy	  	February 28, 2011    /s/ Artur Chodacki
	Name	  	Position	  	Date and signature

  
 - 19 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00185-of-00352.parquet"}]]